Welcome to our dedicated page for HeartSciences news (Ticker: HSCS), a resource for investors and traders seeking the latest updates and insights on HeartSciences stock.
HeartSciences Inc. reports developments as a healthcare information technology company advancing electrocardiography through artificial intelligence. The company’s MyoVista Insights platform is a cloud-native, device-agnostic ECG management system designed for workflow efficiency, EHR interoperability and deployment of cleared AI-ECG algorithms in clinical workflows.
Recurring updates include commercialization of MyoVista Insights, customer and reference-site agreements with hospitals, health networks and academic programs, interoperability milestones such as Epic Toolbox designation, financial results and shareholder meeting matters. HeartSciences also discusses its MyoVista wavECG device, which is designed to provide conventional ECG functionality while supporting on-device AI-enabled solutions.
Fortitude and HeartSciences (Nasdaq: HSCS) signed a definitive all-stock merger agreement, targeting close in H2 2026. The combined company will operate as Fortitude, led by Fortitude CEO Andrea Childs, and is expected to trade on Nasdaq as “TUDE”, subject to approval.
Fortitude is a vertically-integrated Zcash-focused venture mining platform, currently owned by Digital Currency Group, with annualized production of 157,000 ZEC. DCG is expected to own about 95% of the combined company at closing.
HeartSciences (Nasdaq: HSCS) received European Patent No. EP4252651 for ECG-based assessment of diastolic function, effective as a Unitary Patent from April 29, 2026.
The patent covers AI-driven machine-learning models using ECG and demographic data, extends protection to 19 European countries, and brings HeartSciences’ portfolio to more than 45 granted patents.
HeartSciences (Nasdaq: HSCS) released MyoVista Insights 1.3, introducing an AI-ECG Algorithm Marketplace and integrating Bunkerhill Health’s FDA-cleared ECG-EF algorithm for detecting reduced ejection fraction (LVEF ≤40%) from routine 12-lead ECGs.
AI-ECG assessments are eligible for 2026 Medicare reimbursement under APC 5734 at about $136 per assessment, supporting a recurring SaaS revenue model.
HeartSciences (Nasdaq: HSCS) signed a commercial agreement with North Shore Health to deploy its MyoVista Insights ECG management platform. North Shore is the first hospital deployment within the Cibolo Health network, which includes 127 independent hospitals. The deal represents SaaS-based revenue and advances HeartSciences’ AI-enabled ECG commercialization strategy.
HeartSciences (Nasdaq: HSCS) signed a commercial SaaS agreement with St. Vincent Health on May 5, 2026, marking its first mainstream revenue-generating deployment of MyoVista Insights™ after the platform's full launch at the American College of Cardiology annual session.
The cloud-native, device-agnostic ECG management platform is offered as recurring SaaS, supports EHR interoperability, cleared AI-ECG algorithms, and the company says it is in active commercial discussions with additional providers.
HeartSciences (Nasdaq: HSCS) reminds shareholders to submit voting instructions ahead of its virtual Annual Meeting on April 30, 2026 at 10:00 a.m. ET. Shareholders of record as of March 6, 2026 may vote by Internet at www.voteproxy.com or follow materials on the company proxy portal. Proxies must be submitted before 11:59 p.m. ET on April 29, 2026. For help, contact Advantage Proxy or review the definitive Proxy Statement filed on March 17, 2026 available through the company portal.
HeartSciences (Nasdaq: HSCS) announced that its MyoVista Insights platform received Epic Toolbox designation for the ECG Management System category on March 25, 2026. The cloud-native platform supports HL7v2 order/results, SSO, and SMART on FHIR to integrate with Epic EHR workflows.
This designation signals that MyoVista Insights meets Epic’s recommended practices for ECG integrations and is listed on Epic Showroom, enabling clinicians to access the platform within existing EHR workflows.
HeartSciences (Nasdaq: HSCS) will present at the Investor Summit Group Virtual Conference on March 25, 2026 at 12:30 pm ET and will host virtual one-on-one investor meetings on March 26, 2026. CEO Andrew Simpson will outline the company strategy, recent milestones, and near-term growth catalysts.
Registration for the presentation and one-on-one meetings is available via HeartSciences investor registration links.
HeartSciences (Nasdaq: HSCS) reported fiscal Q3 2026 results and a business update. The company has no meaningful revenue for FQ3, reported $3.4M cash and $2.7M shareholders' equity as of Jan 31, 2026, and advanced commercialization of its MyoVista Insights platform.
Key operational milestones include an MDDS regulatory classification for MyoVista Insights, a significant platform upgrade released March 13, 2026, and a December 2025 FDA 510(k) submission for the MyoVista wavECG device.
HeartSciences (Nasdaq: HSCS) announced on February 5, 2026 that the University of the West of England has adopted its MyoVista Insights™ platform and MyoVista® wavECG™ device as exclusive ECG technologies to create an ECG Education and Technology Reference Center.
The center will be used across UWE cardiac and physiological science programs to train NHS-focused cardiac scientists, provide real-world validation in education and research settings, and support future clinical adoption discussions with NHS trusts, strengthening HeartSciences’ UK positioning.